MCID: SFT004
MIFTS: 10

Soft Tissue Sarcoma Childhood

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Soft Tissue Sarcoma Childhood

MalaCards integrated aliases for Soft Tissue Sarcoma Childhood:

Name: Soft Tissue Sarcoma Childhood 53

Classifications:



Summaries for Soft Tissue Sarcoma Childhood

MalaCards based summary : Soft Tissue Sarcoma Childhood is related to rhabdomyosarcoma and soft tissue sarcoma. The drugs Doxorubicin and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone and liver.

Related Diseases for Soft Tissue Sarcoma Childhood

Diseases related to Soft Tissue Sarcoma Childhood via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 rhabdomyosarcoma 9.9
2 soft tissue sarcoma 9.9

Symptoms & Phenotypes for Soft Tissue Sarcoma Childhood

Drugs & Therapeutics for Soft Tissue Sarcoma Childhood

Drugs for Soft Tissue Sarcoma Childhood (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 3 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Liposomal doxorubicin Phase 3 31703
11 Topoisomerase Inhibitors Phase 3
12 Alkylating Agents Phase 3
13 Antineoplastic Agents, Phytogenic Phase 3
14 Tubulin Modulators Phase 3
15 Anti-Bacterial Agents Phase 3
16 Immunosuppressive Agents Phase 3
17 Antibiotics, Antitubercular Phase 3
18 Immunologic Factors Phase 3
19
Isophosphamide mustard Phase 3 0
20 Antimitotic Agents Phase 3
21 Antirheumatic Agents Phase 3
22 Antineoplastic Agents, Alkylating Phase 3
23 Etoposide phosphate Phase 3
24 Anti-Infective Agents Phase 3
25 Nucleic Acid Synthesis Inhibitors Phase 3
26
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
27
Tamoxifen Approved Phase 2 10540-29-1 2733526
28
Sodium citrate Approved, Investigational Phase 2 68-04-2
29
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
30
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
31
Lenograstim Approved, Investigational Phase 2 135968-09-1
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
33
Rubitecan Investigational Phase 2 91421-42-0
34
Camptothecin Experimental Phase 2 7689-03-4
35 Protein Kinase Inhibitors Phase 2
36 Imatinib Mesylate Phase 2 220127-57-1 123596
37 Hormones Phase 2
38 Estrogens Phase 2
39 Citrate Phase 2
40 Selective Estrogen Receptor Modulators Phase 2
41 Estrogen Receptor Modulators Phase 2
42 Hormone Antagonists Phase 2
43 Estrogen Receptor Antagonists Phase 2
44 Liver Extracts Phase 2
45 Antineoplastic Agents, Hormonal Phase 2
46 Estrogen Antagonists Phase 2
47 Bone Density Conservation Agents Phase 2
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
49 topoisomerase I inhibitors Phase 2
50 razoxane Phase 2

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
4 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
5 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
6 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
7 A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
8 A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma Active, not recruiting NCT00077285 Phase 2 carboplatin;cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
9 Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
10 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
11 Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias Completed NCT00030108 Phase 1 ixabepilone
12 A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma Completed NCT01433237
13 LABORATORY STUDIES OF SOFT TISSUE SARCOMAS Completed NCT00900341
14 Clinical and Biological Predictors of Therapy-Related Leukemia Completed NCT00003793
15 A Pilot Study for Soft Tissue Sarcoma Completed NCT00662233 Early Phase 1 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate

Search NIH Clinical Center for Soft Tissue Sarcoma Childhood

Genetic Tests for Soft Tissue Sarcoma Childhood

Anatomical Context for Soft Tissue Sarcoma Childhood

MalaCards organs/tissues related to Soft Tissue Sarcoma Childhood:

41
Bone, Liver

Publications for Soft Tissue Sarcoma Childhood

Variations for Soft Tissue Sarcoma Childhood

Expression for Soft Tissue Sarcoma Childhood

Search GEO for disease gene expression data for Soft Tissue Sarcoma Childhood.

Pathways for Soft Tissue Sarcoma Childhood

GO Terms for Soft Tissue Sarcoma Childhood

Sources for Soft Tissue Sarcoma Childhood

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....